ONCT Oncternal Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ONCT

Price (delayed)

$0.36

Market cap

$21.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.72

Enterprise value

$6.65M

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on ...

Highlights
The EPS is up by 11% year-on-year and by 5% since the previous quarter
Oncternal Therapeutics's debt has soared by 180% YoY but it has decreased by 7% from the previous quarter
Oncternal Therapeutics's net income has increased by 2.9% QoQ but it has decreased by 2.1% YoY
The gross profit has plunged by 65% YoY and by 24% from the previous quarter
ONCT's revenue has dropped by 65% year-on-year and by 24% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.oncternal.com
Peers: OMGA

Key stats

What are the main financial stats of ONCT
Market
Shares outstanding
58.97M
Market cap
$21.23M
Enterprise value
$6.65M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.57
Price to sales (P/S)
32.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.08
Earnings
Revenue
$659,000
EBIT
-$41.72M
EBITDA
-$41.53M
Free cash flow
-$34.75M
Per share
EPS
-$0.72
Free cash flow per share
-$0.59
Book value per share
$0.63
Revenue per share
$0.01
TBVPS
$0.73
Balance sheet
Total assets
$43.2M
Total liabilities
$6.2M
Debt
$342,000
Equity
$37M
Working capital
$37.34M
Liquidity
Debt to equity
0.01
Current ratio
8.25
Quick ratio
7.82
Net debt/EBITDA
0.35
Margins
EBITDA margin
-6,302.1%
Gross margin
100%
Net margin
-6,330%
Operating margin
-6,675.7%
Efficiency
Return on assets
-75.5%
Return on equity
-85.3%
Return on invested capital
-139.7%
Return on capital employed
-109.7%
Return on sales
-6,330%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ONCT stock price

How has the Oncternal Therapeutics stock price performed over time
Intraday
2.56%
1 week
10.77%
1 month
12.5%
1 year
-61.69%
YTD
-64%
QTD
20%

Financial performance

How have Oncternal Therapeutics's revenue and profit performed over time
Revenue
$659,000
Gross profit
$659,000
Operating income
-$43.99M
Net income
-$41.72M
Gross margin
100%
Net margin
-6,330%
Oncternal Therapeutics's net margin has plunged by 191% YoY and by 27% from the previous quarter
The gross profit has plunged by 65% YoY and by 24% from the previous quarter
ONCT's revenue has dropped by 65% year-on-year and by 24% since the previous quarter
The operating margin has declined by 28% since the previous quarter

Growth

What is Oncternal Therapeutics's growth rate over time

Valuation

What is Oncternal Therapeutics stock price valuation
P/E
N/A
P/B
0.57
P/S
32.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.08
The EPS is up by 11% year-on-year and by 5% since the previous quarter
ONCT's price to book (P/B) is 72% less than its 5-year quarterly average of 2.0 and 19% less than its last 4 quarters average of 0.7
ONCT's equity is down by 46% YoY and by 18% from the previous quarter
ONCT's revenue has dropped by 65% year-on-year and by 24% since the previous quarter
ONCT's price to sales (P/S) is 6% higher than its 5-year quarterly average of 30.3 but 3.9% lower than its last 4 quarters average of 33.5

Efficiency

How efficient is Oncternal Therapeutics business performance
The return on sales has dropped by 191% year-on-year and by 27% since the previous quarter
ONCT's return on equity has dropped by 62% year-on-year and by 13% since the previous quarter
The return on assets has dropped by 56% year-on-year and by 12% since the previous quarter
The return on invested capital is up by 24% since the previous quarter

Dividends

What is ONCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ONCT.

Financial health

How did Oncternal Therapeutics financials performed over time
The company's total assets fell by 43% YoY and by 15% QoQ
The current ratio has contracted by 20% from the previous quarter and by 16% YoY
Oncternal Therapeutics's debt is 99% less than its equity
Oncternal Therapeutics's debt has soared by 180% YoY but it has decreased by 7% from the previous quarter
ONCT's equity is down by 46% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.